Infliximab administered with shortened infusion times in a specialized IBD infusion unit: a prospective cohort study.

Background And Aims: Biological therapy with anti TNF agents requires parenteral administration and in the case of infliximab this involves in hospital treatment. We aimed to prospectively assess the safety and tolerance of infliximab infusion in patients with IBD in a specialized unit adhering to strict standard operation procedures including switch to accelerated 1h infusions.

Methods: A prospective audit of a referral center IBD infusion unit was performed.